BACKGROUND: Influenza vaccination is recommended to cancer patients undergoing chemotherapy, but vaccine coverage remains low. During the 2009 influenza pandemic, French recommendations were to vaccinate immunocompromised patients with two doses of adjuvanted vaccine. This study aimed to evaluate vaccine immunogenicity in cancer patients receiving chemotherapy. PATIENTS AND METHODS: VACANCE is a prospective open-label study that evaluated the immunogenicity and safety of two doses of AS03A-adjuvanted H1N1v vaccine in cancer patients receiving cytotoxic and/or targeted therapies. Serum haemagglutination-inhibited antibody titres against influenza A H1N1v were measured at days 1, 21, and 42, to estimate the proportion of participants with antibody titres ≥ 1 : 40 [seroprotection rate (SPR)], the efficacy of seroconversion, and factors that increased the geometric mean titre. RESULTS: Sixty-five patients were included. At baseline, 5% of patients had vaccine strain titres of specific haemagglutination inhibition antibodies that were ≥ 1 : 40. After one and two doses of vaccine, SPRs were 48% and 73%, respectively, and seroconversion rates were 44% and 73%, respectively. Vaccine-related adverse events were mild to moderate. CONCLUSIONS: A single dose of AS03-adjuvanted A/H1N1 vaccine triggered a low immune response in cancer patients on chemotherapy depending on their treatment type and frequency. Two doses are needed for these cancer patients.
BACKGROUND: Influenza vaccination is recommended to cancerpatients undergoing chemotherapy, but vaccine coverage remains low. During the 2009 influenza pandemic, French recommendations were to vaccinate immunocompromised patients with two doses of adjuvanted vaccine. This study aimed to evaluate vaccine immunogenicity in cancerpatients receiving chemotherapy. PATIENTS AND METHODS: VACANCE is a prospective open-label study that evaluated the immunogenicity and safety of two doses of AS03A-adjuvanted H1N1v vaccine in cancerpatients receiving cytotoxic and/or targeted therapies. Serum haemagglutination-inhibited antibody titres against influenza A H1N1v were measured at days 1, 21, and 42, to estimate the proportion of participants with antibody titres ≥ 1 : 40 [seroprotection rate (SPR)], the efficacy of seroconversion, and factors that increased the geometric mean titre. RESULTS: Sixty-five patients were included. At baseline, 5% of patients had vaccine strain titres of specific haemagglutination inhibition antibodies that were ≥ 1 : 40. After one and two doses of vaccine, SPRs were 48% and 73%, respectively, and seroconversion rates were 44% and 73%, respectively. Vaccine-related adverse events were mild to moderate. CONCLUSIONS: A single dose of AS03-adjuvanted A/H1N1 vaccine triggered a low immune response in cancerpatients on chemotherapy depending on their treatment type and frequency. Two doses are needed for these cancerpatients.
Authors: Andrew R Branagan; Eamon Duffy; Randy A Albrecht; Dennis L Cooper; Stuart Seropian; Terri L Parker; Geliang Gan; Fangyong Li; Daniel Zelterman; Chandra Sekhar Boddupalli; Lin Zhang; Rakesh Verma; Thomas M Ferencz; Madhav V Dhodapkar Journal: Clin Lymphoma Myeloma Leuk Date: 2017-03-07
Authors: Yiqing Xu; Nanda Methuku; Praveena Coimbatore; Theresa Fitzgerald; Yiwu Huang; Ying-Yi Xiao; Murali Pagala; Shachi Gupta; William Solomon; Philip Rubin; John Treanor; Alan Astrow; Howard Minkoff; Jay S Cooper Journal: Oncologist Date: 2012-01-12
Authors: Roy E Strowd; Katrina Swett; Michele Harmon; Annette F Carter; Aurora Pop-Vicas; Michael Chan; Stephen B Tatter; Thomas Ellis; Maria Blevins; Kevin High; Glenn J Lesser Journal: Neuro Oncol Date: 2014-04-08 Impact factor: 12.300
Authors: Andreas F Hottinger; Anne-Claude C George; Michael Bel; Laurence Favet; Christophe Combescure; Sara Meier; Stéphane Grillet; Klara Posfay-Barbe; Laurent Kaiser; Claire-Anne Siegrist; Pierre-Yves Dietrich Journal: Oncologist Date: 2012-02-21
Authors: Karel Balihar; Jana Kozeluhova; Vaclav Hejda; Michal Krcma; Daniel Lysak; Jitka Gorcikova; Ondrej Hes; Martin Matejovic Journal: Wien Klin Wochenschr Date: 2013-10-23 Impact factor: 1.704